Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 18 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Noradrenalin and albumin effectively treats type 1 hepatorenal syndrome

Type 1 hepatorenal syndrome can be safely and effectively treated using noradrenalin combined with albumin and furosemide finds a pilot study in the current issue of the journal Hepatology.

News image

fiogf49gjkf04

Scientists have known for almost half a century that hepatorenal syndrome (HRS) results from an intense active vasoconstriction of the renal arteries in an otherwise healthy kidney in the setting of advanced cirrhosis, or less commonly, acute liver failure.

The effect of this renal vasoconstriction is to dramatically reduce glomerular filtration rate (GFR), leading to renal failure.

However, because of the absence of any structural abnormalities in the kidneys of patients suffering HRS, physicians have always considered the disease to be theoretically reversible.

Despite this, all previous pharmacological and non-pharmacological therapies used to reverse HRS have proven unsuccessful, with liver transplantation being the only procedure known to improve renal function in such patients.

It is believed that renal vasoconstriction in HRS patients is the final consequence of an extreme vasodilation of the splanchnic arterial circulation.

This results in a reduction of the effective arterial blood volume (that is, the blood volume that is sensed by the central part of the arterial circulation) and an abnormal distribution of arterial blood volume.

This ultimately leads to a reduction in blood flow to all extra-splanchnic areas, including the kidneys.

A new therapeutic approach to reversing HRS has been the use of vasoconstrictors such as vasopressin analogues.

Administration of these drugs has been shown to greatly improve circulatory function in HRS, along with increased arterial pressure and a near-normalization of the activity of the major endogenous vasoconstrictor systems (renin-angiotensin system and sympathetic nervous system).

In addition, these effects are also associated with improved renal function, with marked increases in renal plasma flow, GFR, urine volume and serum sodium concentration in about two-thirds of patients treated.

A pilot study has now examined the efficacy and safety of noradrenalin (NA) in the treatment of type 1 HRS (the clinical form characterized by rapidly progressive renal failure).

Between 1998 and 2000, 12 consecutive patients with type 1 HRS (7 men, 5 women; mean age 54 years; mean Child-Pugh score 11.3) were given intravenous NA (0.5-3 mg/h), in combination with intravenous albumin and furosemide.

NA was administered for an average of 10 days, at a mean dose of 0.8 mg/h.

HRS reversal:
Occurred in 83% of noradrenalin-treated patients.
Hepatology

In 10 of the 12 patients (83%), reversal of HRS was observed after a median of 7 days (range 5-10 days).

Serum creatinine levels fell from 358 ± 161 to 145 ± 78 µmol/l, while creatinine clearance rose from 13 ± 9 to 40 ± 15 ml/min and urinary sodium output increased from 8 ± 14 to 52 ± 72 mEq/d.

The changes in renal function under NA treatment were associated with an increase in mean arterial pressure (MAP; 65 ± 7 to 73 ± 9 mm Hg).

A marked reduction in active renin (565 ± 989 to 164 ± 196 ng/l) and aldosterone plasma concentrations (1,945 ± 1,931 to 924 ± 730 ng/ml) was also observed.

There was one episode of reversible myocardial hypokinesia (in a patient on 1.5 mg/h NA) that did not recur after a dose reduction.

The research group that carried out the study concludes that "NA combined with albumin and furosemide appears effective and safe for the treatment of type 1 HRS."

However, writing in an accompanying editorial, Dr Pere Ginès and Dr Mónica Guevara caution that this study, along with previous studies using vasoconstrictors for HRS "raise important questions from a therapeutic and pathophysiologic perspective that need to be addressed in future studies."

Hepatology 2002; 36(2): 374-380
01 August 2002

Go to top of page Email this page Email this page to a colleague

 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Medication nonadherence and health care costs
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Socioeconomic characteristics in diverticular disease
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Barriers to hepatitis C treatment
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 31 October 2017 
Endoscopic indices of disease activity for Crohn’s
 31 October 2017 
Follow-up of positive results on fecal blood tests
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Fecal microbiota transplantation
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy
 24 October 2017 
Eosinophilic esophagitis with swallowed topical corticosteroids
 24 October 2017 
Meta-analysis in nutritiona research
 23 October 2017 
NAFLD-related hepatocellular carcinoma in liver resection
 23 October 2017 
Outcome of hepatic sarcoidosis
 20 October 2017 
Hospital readmissions reduction program
 20 October 2017 
Conversion of planned colonoscopy to sigmoidoscopy
 19 October 2017 
Fecal immunochemical tests in colorectal cancer screening
 19 October 2017 
Current management of chylous ascites

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us